Search icon

KODIKAZ THERAPEUTIC SOLUTIONS, INC.

Company Details

Name: KODIKAZ THERAPEUTIC SOLUTIONS, INC.
Jurisdiction: New York
Legal type: FOREIGN BUSINESS CORPORATION
Status: Active
Date of registration: 02 May 2018 (7 years ago)
Entity Number: 5334304
ZIP code: 10014
County: Erie
Place of Formation: Delaware
Address: 180 VARICK STREET, 6TH FLOOR, NEW YORK, NY, United States, 10014

Chief Executive Officer

Name Role Address
ANTHONY JOHNSON Chief Executive Officer 180 VARICK STREET, 6TH FLOOR, NEW YORK, NY, United States, 10014

DOS Process Agent

Name Role Address
KODIKAZ THERAPEUTIC SOLUTIONS, INC. DOS Process Agent 180 VARICK STREET, 6TH FLOOR, NEW YORK, NY, United States, 10014

U.S. Small Business Administration Profile

The U.S. Small Business Administration (SBA) helps Americans start, grow, and build resilient businesses.

Note: SBA was created in 1953 as an independent agency of the federal government to aid, counsel, assist and protect the interests of small business concerns; preserve free competitive enterprise; and maintain and strengthen the overall economy of our nation. SBA reviews Congressional and testifies on behalf of small businesses. It assesses the impact of regulatory burden on small businesses.

Phone Number:
E-mail Address:
Contact Person:
ANTHONY JOHNSON
Ownership and Self-Certifications:
Hispanic American, Self-Certified Small Disadvantaged Business
User ID:
P2389828

History

Start date End date Type Value
2018-05-02 2020-07-14 Address 428 LAKEFRONT BOULEVARD, BUFFALO, NY, 14202, USA (Type of address: Service of Process)

Filings

Filing Number Date Filed Type Effective Date
220927001130 2022-09-27 BIENNIAL STATEMENT 2022-05-01
200714060554 2020-07-14 BIENNIAL STATEMENT 2020-05-01
180502000789 2018-05-02 APPLICATION OF AUTHORITY 2018-05-02

USAspending Awards / Financial Assistance

Date:
2021-08-11
Awarding Agency Name:
National Science Foundation
Transaction Description:
SBIR PHASE I: HORIZONTAL GENOMIC TRANSFER TECHNOLOGY: BIOENGINEERING DNA SEQUENCES FOR THE CREATION OF A NON-VIRAL TARGETED CANCER CELL SPECIFIC GENE THERAPY PLATFORM
Obligated Amount:
255831.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00

Date of last update: 23 Mar 2025

Sources: New York Secretary of State